Dl-2-氨基丁酸置于l-Amino Acid Oxidase 硼烷铵络合物,氧气,甲酸铵体系中,用 水 用作溶剂,化学反应 5.0H,以64%的收率获得d-2-氨基丁酸 参考文献:Amine-boranes: Effective Reducing Agents For The Deracemisation Of Dl-Amino Acids Using L-Amino Acid Oxidase From Proteus Myxofaciens 标题:Amine-boranes: Effective Reducing Agents For The Deracemisation Of Dl-Amino Acids Using L-Amino Acid Oxidase From Proteus Myxofaciens 摘要:The Deracemisation Of Dl-Alpha-Aluino Acids Using L-Amino Acid Oxidase From Proteus Myxofaciens And Amine-Boranes As Chemical Reducing Agents Has Been Investigated. Amine-Boranes Were Found To Be Of Particular Interest In Terms Of Reactivity And Chemoselectivity Compared To Sodium Borohydride And Cyanoborohydride. Starting From The Racemate,A Range Of D-Amino Acids Were Obtained In Yields Of Up To 90%,And E.C. >99%. (C) 2002 Elsevier Science Ltd. All Rights Reserved. Doi:10.1016/s0040-4039(01)02233-X
专利号:US-4396542-A 优先权日:1980-02-14 标 题 :Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production 发明人:WENGER ROLAND 权利人:SANDOZ LTD 摘要:A method for the total synthesis of cyclosporins, in particular Cyclosporin A, cyclosporins produced in accordance with the method of the invention and novel intermediates, in particular novel [1S, 2R, 3R]- and [1R, 2S, 3S]-1-nitrilo-1-carbonyl-3-methyl-2-oxy-heptanes and -hept-5-enes, employed in the method of the invention.
专利号:US-7459443-B2 优先权日:1999-04-08 标 题 :Synthesis of biologically active compounds in cells 发明人:SERGEEV PAVEL 权利人:SERGEEV PAVEL 摘要:This invention relates to a new method of synthesis of biologically active substances of determined structure directly in the cells of living organisms containing specific RNA or DNA molecules of determined sequence. The method is based on the hybridization of two or more oligomers bound with biologically inactive precursors of biologically active substances to specific RNA or DNA in vivo in the cells of living organisms. After hybridization of the oligomers to RNA or DNA the biologically inactive precursors bound to the 5′ and/or 3′ ends of the oligomers can interact with each other to make biologically active form of the substances. This changing of properties is due to chemical reactions which bind the biologically inactive precursors through a chemical bond into a biologically active form of the whole compound.
专利号:US-9475837-B2 优先权日:2011-12-23 标题 :Process for the synthesis of therapeutic peptides 发明人:HURLEY FIONN; WEGNER KATARZYNA; FOLEY PATRICK 权利人:IPSEN MFG IRELAND LTD 摘要:The present invention relates to a process for the large-scale synthesis of therapeutic peptides using a Sieber Amide resin, which comprises solid-phase Fmoc-chemistry.
专利号:US-4554351-A 优先权日:1980-02-14 标 题:Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production 发明人:WENGER ROLAND 权利人:SANDOZ LTD 摘要:A method for the total synthesis of cyclosporins, in particular Cyclosporin A, cyclosporins produced in accordance with the method of the invention and novel intermediates, in particular novel [1S, 2R, 3R]- and [1R, 2S, 3S]-1-nitrilo-1-carbonyl-3-methyl-2-oxy-heptanes and -hept-5-enes, employed in the method of the invention.
专利号:US-10427126-B2 优先权日:2015-10-28 标题 :System and method for longitudinal analysis of peptide synthesis 发明人:Bannen Ryan; Barilovits Sarah; PATEL JIGAR; SULLIVAN ERIC; TAN JOHN 权利人:ROCHE SEQUENCING SOLUTIONS INC 摘要:The present invention provides a system and method for assessing a synthetic peptide population including interrogating a population of peptide features in the presence of a receptor having an affinity for a binder sequence. The population of peptide features is synthesized over a plurality of synthesis periods and includes a plurality of control peptide features synthesized to have an amino acid sequence including the binder sequence. The control peptide features include a first feature synthesized beginning with a first one of the synthesis periods, and a second feature synthesized beginning after the first one of the synthesis periods such that synthesis of the second control peptide feature is delayed by at least one synthesis period. The method further includes detecting a signal output characteristic of an interaction of the receptor with the control peptide features, the signal output indicative of the fidelity of synthesis of the population of peptide features.
专利号:US-5948693-A 优先权日:1994-09-01 标题:Solid phase synthesis of immunosuppressive agents 发明人:RICH DANIEL H; RAMAN PRAKASH; ANGELL YVONNE M 权利人:WISCONSIN ALUMNI RES FOUND 摘要:The present invention relates generally to cyclosporin analogs, and more paritcularly to methods for the solid-phase synthesis and on-resin cyclization of cyclosporin analogs. Methods are described for the on-resin cyclization of sterically hindered compounds synthesized through solid phase synthesis techniques. The methods utilize solvent, temperature, and washing conditions that allow the efficient on-resin cyclization of compounds like analogs of cyclosporin A.
[参考文献]: Yagi K, Et Al. Spectroscopic Demonstration Of An Initial Stage Of The Complex Of D-Amino Acid Oxidase And Its Substrate D-Alpha-Aminobutyric Acid. Biochem Biophys Res Commun. 1980 Nov 28;97(2):370-4. [参考文献]: Gonalo J L Bernardes, Et Al. Site-Selective Traceless Staudinger Ligation For Glycoprotein Synthesis Reveals Scope And Limitations. Chembiochem. 2011 Jun 14;12(9):1383-6. [参考文献]: Jong-Shik Shin, Et Al. Transaminase-Catalyzed Asymmetric Synthesis Of L-2-Aminobutyric Acid From Achiral Reactants. Biotechnol Lett. 2009 Oct;31(10):1595-9. [参考文献]: Jose A Cuesta-Seijo, Et Al. Continuous β-Turn Fold Of An Alternating Alanyl/homoalanyl Peptide Nucleic Acid. Acta Crystallogr D Biol Crystallogr. 2012 Aug;68(Pt 8):1067-70. [参考文献]: Juan Torras, Et Al. Correlation Between Symmetry Breaker Position And The Preferences Of Conformationally Constrained Homopeptides: A Molecular Dynamics Investigation. Biopolymers. 2008;90(5):695-706.
合成参考文献
摘要:Lange R, Hui Bon Hoa G, Douzou P, Yagi K. Kinetics of primary interaction of D-amino acid oxidase with its substrate. Biochem Int. 1983 May;6(5):693–8.